NASDAQ:RTRX - Retrophin Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$28.40 -0.10 (-0.35 %)
(As of 06/19/2018 10:19 AM ET)
Previous Close$28.62
Today's Range$28.40 - $28.62
52-Week Range$17.90 - $29.77
Volume200 shs
Average Volume317,542 shs
Market Capitalization$1.15 billion
P/E Ratio-19.00
Dividend YieldN/A
Beta1.06
Retrophin logoRetrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase I clinical trial for the treatment of phenylketonuria; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in Phase III clinical trial for the treatment of primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RTRX
CUSIPN/A
Phone760-260-8600

Debt

Debt-to-Equity Ratio0.15
Current Ratio5.07
Quick Ratio4.98

Price-To-Earnings

Trailing P/E Ratio-19.00
Forward P/E Ratio-16.71
P/E GrowthN/A

Sales & Book Value

Annual Sales$154.94 million
Price / Sales7.31
Cash FlowN/A
Price / CashN/A
Book Value$7.46 per share
Price / Book3.81

Profitability

EPS (Most Recent Fiscal Year)($1.50)
Net Income$-59,730,000.00
Net Margins-41.95%
Return on Equity-20.27%
Return on Assets-11.80%

Miscellaneous

Employees173
Outstanding Shares39,860,000

Retrophin (NASDAQ:RTRX) Frequently Asked Questions

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) issued its quarterly earnings results on Tuesday, May, 1st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.25. The biopharmaceutical company had revenue of $38.43 million for the quarter, compared to analyst estimates of $39.32 million. Retrophin had a negative return on equity of 20.27% and a negative net margin of 41.95%. The firm's quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the company earned $0.01 EPS. View Retrophin's Earnings History.

What price target have analysts set for RTRX?

1 Wall Street analysts have issued twelve-month target prices for Retrophin's shares. Their predictions range from $43.00 to $43.00. On average, they anticipate Retrophin's stock price to reach $43.00 in the next year. View Analyst Ratings for Retrophin.

Who are some of Retrophin's key competitors?

Who are Retrophin's key executives?

Retrophin's management team includes the folowing people:
  • Mr. Stephen J. Aselage, Chief Exec. Officer, Pres & Director (Age 67)
  • Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 59)
  • Mr. Neil F. McFarlane, Chief Operating Officer (Age 45)
  • Ms. Elizabeth E. Reed, Sr. VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Dr. William E. Rote, Sr. VP of R&D (Age 55)

Has Retrophin been receiving favorable news coverage?

News headlines about RTRX stock have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Retrophin earned a news impact score of 0.15 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.55 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Retrophin's major shareholders?

Retrophin's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.19%), Millennium Management LLC (2.35%), Point72 Asset Management L.P. (2.33%), Dimensional Fund Advisors LP (2.32%), Northern Trust Corp (1.79%) and Oak Ridge Investments LLC (0.90%). Company insiders that own Retrophin stock include Alvin Shih, Elizabeth E Reed, Neil F Mcfarlane, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.

Which institutional investors are selling Retrophin stock?

RTRX stock was sold by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, Spark Investment Management LLC, BlackRock Inc., Prudential Financial Inc., JPMorgan Chase & Co., Dynamic Technology Lab Private Ltd, Cubist Systematic Strategies LLC and BNP Paribas Arbitrage SA. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Neil F Mcfarlane and William E Rote. View Insider Buying and Selling for Retrophin.

Which institutional investors are buying Retrophin stock?

RTRX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Sphera Funds Management LTD., Point72 Asset Management L.P., A.R.T. Advisors LLC, UBS Group AG, Neuberger Berman Group LLC, Matarin Capital Management LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Retrophin.

How do I buy shares of Retrophin?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Retrophin's stock price today?

One share of RTRX stock can currently be purchased for approximately $28.40.

How big of a company is Retrophin?

Retrophin has a market capitalization of $1.15 billion and generates $154.94 million in revenue each year. The biopharmaceutical company earns $-59,730,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Retrophin employs 173 workers across the globe.

How can I contact Retrophin?

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]


MarketBeat Community Rating for Retrophin (RTRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  412
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.